Last reviewed · How we verify
Insulin Glargine Rescue Medication — Competitive Intelligence Brief
phase 3
Long-acting basal insulin
Insulin receptor
Diabetes
Biologic
Live · refreshed every 30 min
Target snapshot
Insulin Glargine Rescue Medication (Insulin Glargine Rescue Medication) — Merck Sharp & Dohme LLC. Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin Glargine Rescue Medication TARGET | Insulin Glargine Rescue Medication | Merck Sharp & Dohme LLC | phase 3 | Long-acting basal insulin | Insulin receptor | |
| Tresiba | INSULIN DEGLUDEC | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2015-01-01 |
| Levemir | INSULIN DETEMIR | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2005-01-01 |
| Apidra | INSULIN GLULISINE | Sanofi | marketed | Insulin Analog [EPC] | Insulin receptor | 2004-01-01 |
| Novolog | INSULIN ASPART | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2000-01-01 |
| Lantus | INSULIN GLARGINE | Sanofi | marketed | Insulin Analog [EPC] | Insulin receptor | 2000-01-01 |
| Humalog | INSULIN LISPRO | Eli Lilly | marketed | Insulin Analog [EPC] | Insulin receptor | 1996-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Long-acting basal insulin class)
- Sanofi · 12 drugs in this class
- Novo Nordisk A/S · 3 drugs in this class
- Life for a Child Program, Diabetes Australia · 1 drug in this class
- Massachusetts General Hospital · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
- Providence Health & Services · 1 drug in this class
- Rabin Medical Center · 1 drug in this class
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
- University Hospital Tuebingen · 1 drug in this class
- Gan and Lee Pharmaceuticals, USA · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin Glargine Rescue Medication CI watch — RSS
- Insulin Glargine Rescue Medication CI watch — Atom
- Insulin Glargine Rescue Medication CI watch — JSON
- Insulin Glargine Rescue Medication alone — RSS
- Whole Long-acting basal insulin class — RSS
Cite this brief
Drug Landscape (2026). Insulin Glargine Rescue Medication — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-rescue-medication. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab